Moody's Corporation (MCO) Stock Price Today
Aura AI Summary
Key Stats
- $88.86BMarket Cap
- 1,176,025Volume
- FinancialsSector
- $539.6152W High
- $412.2352W Low
- 136 DaysTypical Hold Time
- $94.73BEnterprise Value
- 0.8%Div Yield
- 23% Sell | 77% BuyTrading Activity
Track Moody's Corporation (MCO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Moody's Corporation has traded between a low of $412.23 and a high of $539.61, highlighting its annual price range. Buy and sell Moody's Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Most Recent News
Ozempic market to hit $113.95B by 2032 with 24.9% CAGR driven by rising diabetes and metabolic health demand.
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...

IMUNON's IMNN-001 boosts anti-tumor T-cell activity, improving survival in advanced ovarian cancer Phase 2 trial.
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...

Canary Capital launches first U.S. spot staked INJ ETF on Nasdaq, offering exposure plus staking rewards.
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.